Clinical Trial Update: Study of Prophylactic Topical Dapsone 5% Gel Versus Moisturizer for Cetuximab-induced Papulopustular (Acneiform) Rash in Patients With mCRC or HNSCC Without Previous or Concurrent RT [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing prophylactic topical dapsone 5% gel with moisturizer to prevent cetuximab-induced acneiform rash in patients with metastatic colorecta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Topical dapsone 5% gel (dapsone)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Cetuximab-induced Papulopustular (Acneiform) Rash Who Have, Metastatic Colorectal Cancer or Head and Neck Squamous Cell Carcinoma | Phase 3 | Status: COMPLETED | Results posted: 2017-01-13